Featured Research

from universities, journals, and other organizations

Affordable Anti-rejection Drug As Effective As Higher Cost Option, Study Suggests

Date:
October 14, 2009
Source:
Wake Forest University Baptist Medical Center
Summary:
A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study.

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

Such discoveries are vital in an era of skyrocketing health care costs and debate over health reform, said lead investigator Alan C. Farney, M.D., Ph.D., an associate professor of surgery in the Department of General Surgery, Transplantation Services.

"I think it's very important that the public consider cost, and that they ask their doctors if there are alternatives for them that are less expensive," he said. "Why should we use one drug or intervention over another that is equally effective and a fraction of the cost?"

For the study, published recently in the journal Transplantation, researchers looked at the two most common drugs used for induction immunosuppression therapy with kidney and pancreas transplants:

  • alemtuzumab, a newer drug that costs about $1,000 per single-dose treatment and is marketed under the name CampathTM; and
  • rabbit antithymocyte globulin, which costs about four times more for its multidose treatment than alemtuzumab, and is marketed under the name ThymoglobulinTM.

Both drugs destroy the cells that cause organ rejection during induction immunosuppression therapy – a short-term, early treatment meant to rapidly lower the immune system to prevent rejection until the patient begins taking daily drugs to suppress the immune system.

Though more expensive, rabbit antithymocyte globulin has generally been more commonly prescribed than alemtuzumab at Wake Forest Baptist and other transplant centers because there has been a concern that the newer drug would suppress the immune system too much and lead to infections or cancer, Farney said.

"We want to avoid acute rejection, but we also don't want to pay a price when we're trying to do that by leaving the patient over-immunosuppressed," he said. "We were being cautious, but this study reveals that, through at least two years of follow up, both drugs are equally effective and safe."

In the study of 222 patients receiving either kidney transplants alone, simultaneous kidney-pancreas transplants, or pancreas-after-kidney transplants, researchers found that both drugs showed similar survival rates for the patients (96 percent), the transplanted kidneys (89 percent) and the transplanted pancreases (90 percent). The drugs also had similar infection rates.

From Feb. 1, 2005, to Sept. 1, 2007, transplant patients participating in the study received either alemtuzumab or rabbit antithymocyte globulin, followed by the same course of maintenance drugs. Both groups included patients who varied in age, race, gender and risk – a unique approach with clinical studies, which usually look at a group with similar characteristics.

The researchers wanted to design this study – one of the largest single-institution trials for transplantation drugs – to reflect the actual demographics of the Medical Center's transplant patients, Farney said. Transplantation Services at Wake Forest University Baptist Medical Center performs more than 150 kidney and pancreas transplants each year.

"It represents who we really transplant at Wake Forest Baptist," Farney said. "Other trials are so exclusive that you don't know what the true results are for most people."

As a result of the study, the Wake Forest Baptist Transplant Program has adopted the newer drug as part of its standard anti-rejection protocol for kidney and pancreas transplantation, Farney said.

Co-investigators, all from the Medical Center, are William Doares, Pharm.D., M.A.Ed., Jeffrey Rogers, M.D., Rajinder Singh, M.D., Erica Hartmann, M.D., Lois Hart, Elizabeth Ashcraft, Amber Reeves-Daniel, D.O., Michael Gautreaux, Ph.D., Samy S. Iskandar, M.BB.Ch., Ph.D., Phillip Moore, M.D., Patricia L. Adams, M.D., and Robert J. Stratta, M.D.

The researchers continue to track the study participants annually to determine the long-term outcomes for both drugs.


Story Source:

The above story is based on materials provided by Wake Forest University Baptist Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Wake Forest University Baptist Medical Center. "Affordable Anti-rejection Drug As Effective As Higher Cost Option, Study Suggests." ScienceDaily. ScienceDaily, 14 October 2009. <www.sciencedaily.com/releases/2009/10/091014122047.htm>.
Wake Forest University Baptist Medical Center. (2009, October 14). Affordable Anti-rejection Drug As Effective As Higher Cost Option, Study Suggests. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2009/10/091014122047.htm
Wake Forest University Baptist Medical Center. "Affordable Anti-rejection Drug As Effective As Higher Cost Option, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2009/10/091014122047.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins